Ding T, Hardiman PJ, Petersen I, Wang F-F, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: A systematic review and meta-analysis. 2017.

Kazemi M, Pierson RA, Lujan ME, Chilibeck PD, McBreairty LE, Gordon JJ, et al. Comprehensive evaluation of type 2 diabetes and cardiovascular disease risk profiles in reproductive-age women with polycystic ovary syndrome: A large canadian cohort. J Obstet Gynaecol Can. 2019;41:1453–60.

Article  PubMed  Google Scholar 

Marchesan LB, Ramos RB, Spritzer PM. Metabolic features of women with polycystic ovary syndrome in latin America: A systematic review. Front Endocrinol. 2021. https://doi.org/10.3389/fendo.2021.759835. (Lausanne).

Article  Google Scholar 

Zhang J, Xu JH, Qu QQ, Zhong GQ. Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: A meta-analysis of cohort studies. Front Cardiovasc Med. 2020. https://doi.org/10.3389/fcvm.2020.552421.

Article  PubMed  Google Scholar 

•• Zahid S, Khan MZ, Gowda S, Faza NN, Honigberg MC, Vaught A, et al. Trends, predictors, and outcomes of cardiovascular complications associated with polycystic ovary syndrome during delivery hospitalizations: a national inpatient sample analysis (2002–2019). J Am Heart Assoc. 2022;11(16). https://doi.org/10.1161/JAHA.121.025839. Cardiovascular complications in women with PCOS in over 70,000,000 delivery hospitalizations in the U.S.

Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6–15.

Article  PubMed  Google Scholar 

Daan NMP, Louwers YV, Koster MPH, Eijkemans MJC, De Rijke YB, Lentjes EWG, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: Who is really at risk? Fertil Steril. 2014;102:1444-1451.e3.

Article  PubMed  Google Scholar 

Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian J Endocrinol Metab. 2019;23:326.

Article  PubMed  Google Scholar 

Mumusoglu S, Yildiz BO. Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population. Curr Opin Endocr Metab Res. 2020;12:66–71.

Article  Google Scholar 

•• Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023. https://doi.org/10.1210/clinem/dgad463. International evidence-based guidelines for the assessment and management of women with PCOS.

Dayo OM, Gordon NP, Chandra M, Weintraub ML, Lo JC. Racial and ethnic differences in the prevalence of diagnosed polycystic ovary syndrome in women receiving ambulatory care. Fertil Steril. 2020;114:e402–3.

Article  Google Scholar 

Engmann L, Jin S, Sun F, et al. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. Am J Obstet Gynecol. 2017;216:493.e1-493.e13.

Article  PubMed  Google Scholar 

Hillman JK, Johnson LNC, Limaye M, Feldman RA, Sammel M, Dokras A. Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS. Fertil Steril. 2014;101:530–5.

Article  PubMed  Google Scholar 

Afifi L, Saeed L, Pasch LA, Huddleston HG, Cedars MI, Zane LT, et al. Association of ethnicity, Fitzpatrick skin type, and hirsutism: A retrospective cross-sectional study of women with polycystic ovarian syndrome. Int J Womens Dermatol. 2017;3:37–43.

Article  PubMed  Google Scholar 

Chan JL, Kar S, Vanky E, et al. Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study. Am J Obstet Gynecol. 2017;217:189.e1-189.e8.

Article  PubMed  Google Scholar 

Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020. https://doi.org/10.1016/j.molmet.2020.01.001.

Article  PubMed  Google Scholar 

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36:487–525.

Article  PubMed  Google Scholar 

Harada M. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. Reprod Med Biol. 2022. https://doi.org/10.1002/rmb2.12487.

Article  PubMed  Google Scholar 

•• Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22(7):3789. Review on the role of chornic inflammation in the pathogenesis of PCOS.

Article  PubMed  Google Scholar 

Tola EN, Yalcin SE, Dugan N. The predictive effect of inflammatory markers and lipid accumulation product index on clinical symptoms associated with polycystic ovary syndrome in nonobese adolescents and younger aged women. Eur J Obstet Gynecol Reprod Biol. 2017;214:168–72.

Article  PubMed  Google Scholar 

Abraham Gnanadass S, Divakar Prabhu Y, Valsala Gopalakrishnan A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet. 2021;303:631–43.

Article  PubMed  Google Scholar 

Rudnicka E, Kunicki M, Suchta K, Machura P, Grymowicz M, Smolarczyk R. Inflammatory markers in women with polycystic ovary syndrome. Biomed Res Int. 2020;2020:1–10.

Article  Google Scholar 

Insenser M, Murri M, del Campo R, Martínez-García MÁ, Fernández-Durán E, Escobar-Morreale HF. Gut microbiota and the polycystic ovary syndrome: Influence of Sex, Sex Hormones, and Obesity. J Clin Endocrinol Metab. 2018;103:2552–62.

Article  PubMed  Google Scholar 

Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: From composition to function. Clin Gastroenterol Hepatol. 2019;17:296–306.

Article  PubMed  Google Scholar 

•• Bhandary P, Shetty PK, Manjeera L, Patil P. Hormonal, genetic, epigenetic and environmental aspects of polycystic ovarian syndrome. Gene Rep. 2022;29:101698. Study of over 300 individuals that explores the role of hormonal, genetic, and environmental factors in the pathophysiology of PCOS.

Article  Google Scholar 

•• Barber TM. Why are women with polycystic ovary syndrome obese? Br Med Bull. 2022;143(1):4–15. (This review explores the role of obesity in the pathogenesis of PCOS.)

Article  PubMed  Google Scholar 

Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019;92:108–20.

Article  PubMed  Google Scholar 

Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015;149:R219–27.

Article  PubMed  Google Scholar 

•• Liao W-T, Huang J-Y, Lee M-T, Yang Y-C, Wu C-C. Higher risk of type 2 diabetes in young women with polycystic ovary syndrome: A 10-year retrospective cohort study. World J Diabetes. 2022;13(3):240–50. A longitudinal, 10-year retrospective cohort study explored the rates of type 2 diabetes mellitus in women with PCOS.

Article  PubMed  Google Scholar 

Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the pathogenesis, diagnosis and treatment of pcos: Focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23084110.

Sidhwani S, Scoccia B, Sunghay S, Stephens-Archer CN, Mazzone T, Sam S. Polycystic ovary syndrome is associated with atherogenic changes in lipoprotein particle number and size independent of body weight. Clin Endocrinol. 2011;75:76–82 (Oxf).

Article  Google Scholar 

van der Ham K, Louwers YV, Laven JSE. Cardiometabolic biomarkers in women with polycystic ovary syndrome. Fertil Steril. 2022;117:887–96.

Article  PubMed  Google Scholar 

• Liu Q, Xie YJ, Qu LH, Zhang MX, Mo ZC. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. Elsevier Ltd; 2019;58:447–453. Review on the mechanisms of lipid metabolism abnormalities in the development of PCOS.

Mousa S, Saif A, Fathy M, Mansour M, AbdElhamid AM, Atef A, et al. Assessment of early vascular changes in adult females with polycystic ovary syndrome: correlation with insulin resistance. Gynecol Endocrinol. 2023. https://doi.org/10.1080/09513590.2023.2210226.

Article  PubMed  Google Scholar 

Shi Y, Cui Y, Sun X, Ma G, Ma Z, Gao Q, et al. Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors. Eur J Obstet Gynecol Reprod Biol. 2014;173:66–70.

Article  PubMed  Google Scholar 

Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020;18:23.

Article  PubMed  Google Scholar 

Macut D, Bačević M, Božić-Antić I, et al. Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. Int J Endocrinol. 2015;2015:1–9.

Article  Google Scholar 

•• Zhuang C, Luo X, Wang W, Sun R, Qi M, Yu J. Cardiovascular risk according to body mass index in women of reproductive age with polycystic ovary syndrome: A systematic review and meta-analysis. Front Cardiovasc Med. 2022;9. https://doi.org/10.3389/fcvm.2022.822079.  Recent systemic review and meta-analysis on cardiovascular risk in PCOS and mechanisms underlying these risk factors.

Bahri Khomami M, Boyle JA, Tay CT, Vanky E, Teede HJ, Joham AE, et al. Polycystic ovary syndrome and adverse pregnancy outcomes: Current state of knowledge, challenges and potential implications for practice. Clin Endocrinol. 2018;88:761–9 (Oxf).

Article  Google Scholar 

Tripathy P, Sahu A, Sahu M, Nagy A. Ultrasonographic evaluation of intra-abdominal fat distribution and study of its influence on subclinical atherosclerosis in women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2017;217:18–22.

Article  PubMed  Google Scholar 

Osibogun O, Ogunmoroti O, Kolade OB, Hays AG, Okunrintemi V, Minhas AS, et al. A systematic review and meta-analysis of the association between polycystic ovary syndrome and coronary artery calcification. J Womens Health. 2022;31:762–71.

Article  Google Scholar 

Rashad NM, El-Shal AS, Abomandour HG, Aboelfath AMK, Rafeek MES, Badr MS, et al. Intercellular adhesion molecule-1 expression and serum levels as markers of pre-clinical atherosclerosis in polycystic ovary syndrome. J Ovarian Res. 2019. https://doi.org/10.1186/s13048-019-0566-5.

Article  PubMed  Google Scholar 

• Jabbour R, Ott J, Eppel W, Frigo P. Carotid intima-media thickness in polycystic ovary syndrome and its association with hormone and lipid profiles. PLoS One. 2020;15(4):e0232299. Reported the likelihood of premature atherosclerosis in women with PCOS.

Article  PubMed  Google Scholar 

• Sun D, Wu Y, Ding M, Zhu F. Comprehensive meta-analysis of functional and structural markers of subclinical atherosclerosis in women with polycystic ovary syndrome. Angiology. 2022;73(7):622–34. Comprehensive systematic review and meta-analysis evaluating markers of subclinical atherosclerosis in PCOS.

Article  PubMed  Google Scholar